Vantage Wealth raised its holdings in Agilent Technologies, Inc. (NYSE:A - Free Report) by 20.9% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 132,480 shares of the medical research company's stock after acquiring an additional 22,890 shares during the quarter. Agilent Technologies comprises approximately 3.5% of Vantage Wealth's holdings, making the stock its 22nd largest position. Vantage Wealth's holdings in Agilent Technologies were worth $15,498,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of the business. Brighton Jones LLC lifted its stake in shares of Agilent Technologies by 6.1% in the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company's stock worth $626,000 after buying an additional 270 shares during the last quarter. Caprock Group LLC boosted its holdings in Agilent Technologies by 25.7% during the fourth quarter. Caprock Group LLC now owns 9,698 shares of the medical research company's stock valued at $1,305,000 after acquiring an additional 1,982 shares during the period. Greenleaf Trust grew its position in shares of Agilent Technologies by 3.0% in the fourth quarter. Greenleaf Trust now owns 8,036 shares of the medical research company's stock valued at $1,080,000 after purchasing an additional 231 shares during the last quarter. CENTRAL TRUST Co grew its holdings in Agilent Technologies by 35.5% in the 4th quarter. CENTRAL TRUST Co now owns 2,506 shares of the medical research company's stock valued at $337,000 after buying an additional 657 shares during the last quarter. Finally, KPP Advisory Services LLC raised its stake in Agilent Technologies by 7.0% during the 4th quarter. KPP Advisory Services LLC now owns 3,056 shares of the medical research company's stock valued at $410,000 after purchasing an additional 199 shares during the last quarter.
Analyst Ratings Changes
A has been the topic of several research analyst reports. Robert W. Baird decreased their price target on shares of Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating on the stock in a research report on Thursday, May 22nd. Wells Fargo & Company lowered their price target on Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating on the stock in a research note on Thursday, April 17th. TD Cowen upped their price target on Agilent Technologies to $150.00 and gave the company a "buy" rating in a report on Thursday, May 29th. UBS Group lowered their price objective on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating on the stock in a research report on Thursday, May 29th. Finally, Leerink Partners upped their target price on Agilent Technologies to $135.00 and gave the company a "buy" rating in a research note on Friday, May 30th. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, Agilent Technologies has an average rating of "Moderate Buy" and a consensus target price of $140.15.
View Our Latest Research Report on Agilent Technologies
Agilent Technologies Price Performance
A stock traded down $1.06 during midday trading on Thursday, reaching $113.88. 1,845,345 shares of the company's stock traded hands, compared to its average volume of 1,921,224. The company has a quick ratio of 1.60, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. The company has a market cap of $32.47 billion, a price-to-earnings ratio of 28.12, a PEG ratio of 3.42 and a beta of 1.23. The company has a 50-day simple moving average of $108.11 and a two-hundred day simple moving average of $126.10. Agilent Technologies, Inc. has a 1-year low of $96.43 and a 1-year high of $153.84.
Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings results on Wednesday, May 28th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.05. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The business had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.63 billion. During the same quarter in the prior year, the company earned $1.22 EPS. The firm's quarterly revenue was up 6.0% on a year-over-year basis. On average, analysts anticipate that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.
Agilent Technologies Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 23rd. Stockholders of record on Tuesday, July 1st will be paid a $0.248 dividend. The ex-dividend date is Tuesday, July 1st. This represents a $0.99 annualized dividend and a dividend yield of 0.87%. Agilent Technologies's dividend payout ratio (DPR) is currently 24.44%.
Insider Transactions at Agilent Technologies
In other Agilent Technologies news, VP Rodney Gonsalves sold 1,908 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $121.98, for a total value of $232,737.84. Following the transaction, the vice president now owns 21,786 shares of the company's stock, valued at approximately $2,657,456.28. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel K. Podolsky sold 1,819 shares of the firm's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $116.46, for a total value of $211,840.74. Following the transaction, the director now owns 35,737 shares in the company, valued at approximately $4,161,931.02. This trade represents a 4.84% decrease in their position. The disclosure for this sale can be found here.
Agilent Technologies Company Profile
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Further Reading
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
